BTI-322 for acute rejection after renal transplantation
(1997) Transplantation Proceedings — Vol. 29, n° 5, p. 2353 (1997)
Files
13160.pdf
Restricted Access - Adobe PDF
- 80.73 KB
Details
- Authors
- Abstract
- BTI-322/LO-CD2a, a rat IgG2b, anti-CD2 monoclonal antibody which binds to all human T and natural killer (NK) cells, was first produced at our Institution1 and was first administered to patients on a compassionate-use basis in 1992. Four patients (three with renal allograft rejection and one with graft-versus-host-disease [GVHD]) resistant to standard therapies received treatment with LO-CD2a 10 mg/d intravenously (IV) for up to 12 days, plus steroids. In all cases, the drug was well tolerated, with no evidence of undesirable side effects; significant clinical benefit was demonstrated in each case. In 1993, LO-CD2a was successfully produced in vitro and became known as BTI-322. A study was initiated to evaluate the safety and determine the minimally effective dose of BTI-322 for treatment of either the first episode of acute renal allograft rejection (group AR) or uncontrolled rejection (rescue therapy; group RT).
- Affiliations
Citations
Mourad, M., Besse, T., Malaise, J., Baldi, A., Latinne, D., Bazin, H., Pirson, Y., Hope, J., & Squifflet, J.-P. (1997). BTI-322 for acute rejection after renal transplantation. Transplantation Proceedings, 29(5), 2353. https://doi.org/10.1016/s0041-1345(97)00398-9 (Original work published 1997)